Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lobenzarit. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.51 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.51 |
| ▸ | P2RY4 known ✓ | P51582 | 1/20 | 0.43 |
| ▸ | P2RY12 known ✓ | Q9H244 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobenzarit SCHEMBL31526884 | 1.00 | CYP2C9 (0.51) | CYP2C9MEN1KMT2AGMNNUSP2 | |
| SCHEMBL9691887 | 0.84 | HPGD (0.56) | CYP2C9MEN1KMT2AGMNNUSP2 | |
| Lobenzarit SCHEMBL30753983 | 0.83 | GRIK1 (0.63) | CYP2C9MEN1KMT2AUSP2LMNA | |
| Lobenzarit SCHEMBL187951 | 0.83 | GRIK1 (0.63) | CYP2C9MEN1KMT2AUSP2LMNA | |
| Lobenzarit SCHEMBL7935 | 0.82 | GRIK1 (0.61) | CYP2C9MEN1KMT2AUSP2LMNA | |
| Lobenzarit SCHEMBL1479150 | 0.82 | GRIK1 (0.61) | CYP2C9MEN1KMT2AUSP2LMNA | |
| Lobenzarit SCHEMBL9621335 | 0.82 | GRIK1 (0.61) | CYP2C9MEN1KMT2AUSP2LMNA | |
| Lobenzarit SCHEMBL29453054 | 0.82 | GRIK1 (0.61) | CYP2C9MEN1KMT2AUSP2LMNA | |
| Potassium Ion SCHEMBL28560618 | 0.80 | FABP4 (0.52) | CYP2C9MEN1KMT2AGMNNUSP2 | |
| SCHEMBL10951695 | 0.79 | CYP1A2 (0.61) | CYP2C9MEN1KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0665753-A1 | FLUDARABINE-5'-MONOPHOSPHATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994009791-A1 | FLUDARABINE-5'-MONOPHOSPHATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-05-11 | — | — | WO | disclosed |
| EP-0306708-B1 | NOVEL BENZOTHIAZOLE AND ANTIRHEUMATIC AGENT COMPRISING IT AS AN ACTIVE INGREDIENT | KANEBO, LTD. (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4910211-A | Containing a phenyl substituted in position 2 and an ester in position 4 | KANEBO LTD. (JP) | 1990-03-20 | — | — | US | disclosed |
| EP-0139206-B1 | GAMMA-BUTYROLACTONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND IMMUNOMODULATING COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS | MITSUBISHI KASEI CORPORATION (JP) | 1988-07-20 | — | — | EP | disclosed |
| US-4613613-A | ANTIARTHRITIC AGENTS | MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-23 | — | — | US | disclosed |
| EP-0139206-A1 | Gamma-Butyrolactone derivatives, process for preparing the same and immunomodulating compositions containing the same as active ingredients | MITSUBISHI KASEI CORPORATION (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197401-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | THRB 1625/4885PTGS2 595/4885P2RY4 29/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | THRB 2424/4885PTGS2 2943/4885P2RY4 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.